← Leaderboards
Hans M Spiegel
Children'S National Medical Center
$1,313,541
Attributed
$1,313,541
Total exposure
14
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $56.5K · FY2005–08$100K$75K$50K$25K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,313,541 · 14
By mechanism
U01$1,201,954 · 1
M01$111,587 · 13
Top collaborators
No co-investigators on record.
Most similar at Children'S National Medical Center
Same institution · by research overlap
- John L Sever$901,958
Others in their field
Top investigators on “Clinical Trial Phase I”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$674,722,986
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$549,289,302
- Barton F Haynes · Duke University$532,133,792
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$407,280,377
Research focus
Clinical Trial Phase IPathologic ProcessOpportunistic InfectionsImmunotherapyAids Clinical Trial GroupAids Education /PreventionAdolescence (12-20)Aids VaccinesAidsAnti-Retroviral AgentsAntiretroviral TherapyAntiviral AgentsAntiviral AntibodyAtovaquoneChemopreventionAids /Hiv TestBody SystemChildChild (0-11)Clinical ResearchBehavioral /Social Science Research TagClinical Trial Phase IiCombination ChemotherapyAids/Hiv Problem
Grant awards (15)
ACTG 219C: PEDIATRIC LATE OUTCOME PROTOCOL, VERSION 30 HIV/AIDS$56,493
M01 · FY2008 · RR · contact PI
ACTG 219C: PEDIATRIC LATE OUTCOME PROTOCOL, VERSION 30 HIV/AIDS$14,203
M01 · FY2007 · RR · contact PI
P1030: A PHASE I/II STUDY OF LOPINAVIR/RITONAVIR IN HIV-1 INFECTED INFANTS < 6$2,705
M01 · FY2006 · RR · contact PI
ACTG 219C: PEDIATRIC LATE OUTCOME PROTOCOL, VERSION 40$2,705
M01 · FY2006 · RR · contact PI
HIV SPECIFIC IMMUNE RESPONSES AND DISEASE PROGRESSION IN PEDIATRIC HIV-1 INFECTI$1,350
M01 · FY2006 · RR · contact PI
PACTG P1006: THE EFFECTS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)$1,350
M01 · FY2006 · RR · contact PI
ACTG 219C: PEDIATRIC LATE OUTCOMES PROTOCOL, VERSION 40$9,809
M01 · FY2005 · RR
P1025: PERINATAL CORE PROTOCOL, VERSION 20$6,470
M01 · FY2005 · RR
PACTG 1045: MORPHOLOGIC &METABOLIC ABNORMALITY IN HIV-INFECT &UNINFECT CHILD$4,853
M01 · FY2005 · RR
PACTG 1030: PHASE I/II STUDY OF LOPINAVIR/RITONAVIR IN$4,366
M01 · FY2005 · RR
PACTG P1006: THE EFFECTS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)$3,558
M01 · FY2005 · RR
PACTG 1010: ANTIRETROVIRAL THERAPY ON BODY COMPOSITION$2,425
M01 · FY2005 · RR
PACTG 351 PHASE 1/11TRIAL OF CD4-1GG2 HIV-INFECTED CHIL$1,300
M01 · FY2005 · RR
WASHINGTON D.C. CONSORTIUM PEDIATRIC AIDS CLINICAL TRIAL$284,128
U01 · FY2002 · AI
WASHINGTON D.C. CONSORTIUM PEDIATRIC AIDS CLINICAL TRIAL$917,826
U01 · FY2001 · AI